Efficacy News and Research

RSS
Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

TD2 and Flagship Biosciences offer combined oncology and pathology services

TD2 and Flagship Biosciences offer combined oncology and pathology services

IEHA, Cintas release list of best practices for reducing HAIs within healthcare facility

IEHA, Cintas release list of best practices for reducing HAIs within healthcare facility

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

Metanx promotes restoration of lost cutaneous sensation in Diabetic Neuropathy patients

Metanx promotes restoration of lost cutaneous sensation in Diabetic Neuropathy patients

Study: Removal of B lymphocytes can reverse aging process

Study: Removal of B lymphocytes can reverse aging process

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Scientists to develop enzyme that protects against nerve agents

Scientists to develop enzyme that protects against nerve agents

Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint

Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint

Patients with chronic depression can benefit from pioneering neurosurgical treatment

Patients with chronic depression can benefit from pioneering neurosurgical treatment

HealthStream, Laerdal launch Simcenter simulation management platform for healthcare institutions

HealthStream, Laerdal launch Simcenter simulation management platform for healthcare institutions

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry

Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

FDA approves Clinical Data's Viibryd for major depressive disorder

FDA approves Clinical Data's Viibryd for major depressive disorder

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.